Evidence map›Paper›PMID 39636864›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Intricate ribosome composition and translational reprogramming in epithelial-mesenchymal transition.

Chloé Morin, Agnès Baudin-Baillieu, Flora Nguyen Van Long, Caroline Isaac, Laure Bidou, Hugo Arbes, Pauline François, Roxane M Pommier, Annie Adrait, Akari Saku and 17 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Role of Ubiquitin-regulated EMT in Cancer Metastasis and Chemoresistance.International journal of biological sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Chloé Morin"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.ORCID 0000-0003-4568-5587
Agnès Baudin-BaillieuUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell, Gif-sur-Yvette 91198, France.
Flora Nguyen Van Long"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.
Caroline Isaac"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.
Laure BidouUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell, Gif-sur-Yvette 91198, France.ORCID 0000-0002-3973-4058
Hugo ArbesUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell, Gif-sur-Yvette 91198, France.ORCID 0000-0001-5718-6529
Pauline FrançoisUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell, Gif-sur-Yvette 91198, France.
Roxane M PommierBioinformatics Platform Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Synergie Lyon Cancer Fondation, Lyon 69008, France.
Annie AdraitUniv. Grenoble Alpes, INSERM, CEA, UA13 BGE, CNRS, CEA, FR2048, Grenoble 38000, France.
Akari Saku"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.
Stephanie Gran-Ruaz"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.
Camélia Machkouri"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.
Christophe VanbelleCell Imaging Platform, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.
Romain MorichonCytometry and Imagery platform Saint-Antoine, SU Centre de Recherche Saint-Antoine, Paris F75012, France.
Mathieu BoissanSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris 75651, France.
Frédéric Catez"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.ORCID 0000-0001-8255-9091
Anthony FerrariBioinformatics Platform Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Synergie Lyon Cancer Fondation, Lyon 69008, France.
Anne-Pierre Morel"EMT and Cancer Cell Plasticity" Team, Centre Léon Bérard, Lyon 69008, France.ORCID 0000-0001-9794-9615
Yohann CoutéUniv. Grenoble Alpes, INSERM, CEA, UA13 BGE, CNRS, CEA, FR2048, Grenoble 38000, France.ORCID 0000-0003-3896-6196
Sophie ChatUniv. Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR6290, Rennes 35000, France.
Emmanuel GiudiceUniv. Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR6290, Rennes 35000, France.
Reynald GilletUniv. Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR6290, Rennes 35000, France.
Alain PuisieuxInstitut Curie, PSL Research University, Paris 75005, France.
Caroline Moyret-Lalle"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.
Jean-Jacques Diaz"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.ORCID 0000-0002-7914-4319
Olivier Namy *Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell, Gif-sur-Yvette 91198, France.ORCID 0000-0002-1143-5961
Virginie Marcel *"Ribosome, Translation and Cancer" Team, LabEx DEVweCAN, Institut Convergence Plascan, LYriCAN+, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69008, France.ORCID 0000-0002-9557-8221

Funding

Institut National Du Cancer (INCa) ARC_INCa_LNCC_7625
6 · The paper itself

Abstract

Epithelial-mesenchymal transition (EMT) involves profound changes in cell morphology, driven by transcriptional and epigenetic reprogramming. However, evidence suggests that translation and ribosome composition also play key roles in establishing pathophysiological phenotypes. Using genome-wide analyses, we reported significant rearrangement of the translational landscape and machinery during EMT. Specifically, a cell line overexpressing the EMT transcription factor ZEB1 displayed alterations in translational reprogramming and fidelity. Furthermore, using riboproteomics, we unveiled an increased level of the ribosomal protein RPL36A in mesenchymal ribosomes, indicating precise tuning of ribosome composition. Remarkably, RPL36A overexpression alone was sufficient to trigger the acquisition of mesenchymal features, including a switch in the molecular pattern, cell morphology, and behavior, demonstrating its pivotal role in EMT. These findings underline the importance of translational reprogramming and fine-tuning of ribosome composition in EMT.

Indexed as

Epithelial-Mesenchymal TransitionProtein BiosynthesisRibosomal ProteinsRibosomesZinc Finger E-box-Binding Homeobox 1Cellular ReprogrammingHumansRibosomal ProteinsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1EMTribosomeRPL36AtranslationZEB1

Identifiers

PMID39636864
PMCPMC11648652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.